Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Placebo-Controlled Parallel Group Study Of Safety And Efficacy Of Isomyosamine In Treating Sarcopenia After Hip Or Femoral Fracture In Gerontological Population

NCT06942182 is registered in ClinicalTrials.gov with TNF Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06942182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06942182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Placebo-Controlled Parallel Group Study Of Safety And Efficacy Of Isomyosamine In Treating Sarcopenia After Hip Or Femoral Fracture In Gerontological Population
Lead sponsor
TNF Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
March 1, 2026
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

frailty, frailty in older adults, frailty/sarcopenia, sarcopenia in elderly